Poniard Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript

Poniard Pharmaceuticals, Inc. (PARD)

Q2 2010 Earnings Call

August 9, 2010 4:30 pm ET

Executives

Susan Neath - Investor Relations

Ronald Martell – CEO

Dr. Michael Perry - President & CMO

Mike Jackson – Interim CFO

Analysts

Simos Simeonidis - Rodman & Renshaw

Gary Polakoff - UBS

Presentation

Operator

Good day, and welcome to the Poniard Pharmaceuticals Second Quarter 2010 Earnings Conference Call. Today’s conference is being recorded.

At this time, I would like to turn the conference over to Susan Neath. Please go ahead, Susan.

Susan Neath

Good afternoon, and thank you for joining us to discuss the results of Poniard Pharmaceuticals Second Quarter 2010 Earnings Conference Call.

Poniard issued a press release today that is available on the company’s website at www.poniard.com.

Compare to:
Previous Statements by PARD
» Poniard Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
» Poniard Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
» Poniard Pharmaceuticals Inc Q4 2007 Earnings Call Transcript

Comments made on this call will contain forward-looking statements relating to, among other things, the commercial potential of the company’s Picoplatin and product candidates, the company’s corporate strategies and objectives, regulatory and partnering efforts, product development activities, clinical and regulatory goals, financial conditions, future expectations and prospects.

Actual results and events may differ materially from those indicated in these forward-looking statements based on a number of important factors, risks and uncertainties including the company’s anticipated future operating losses, future capital requirement and ability to obtain future funding, the risk that strategic partnerships may not be established on a timely on terms that are ultimately favorable to the company or at all, the potential safety, efficacy and commercial viability of Picoplatin, the risk of the company’s additional analysis of data from clinical trials of Picoplatin may produce inconclusive results or may be inconsistent with previously announced results or previously conducted trials, the company’s ability to retain key personnel, competition from third-parties, the company’s ability to preserve and protect intellectual property rights, the company’s dependence on third-party manufacturers, supplies and other contractors, changes in technology, government regulation and general market conditions, the receipt and timing of FDA and other required regulatory approvals and the other risk and uncertainties described in the company’s reports filed with the Securities and Exchange Commission including the company’s Annual Report on Form 10-K for the year ended December 31, 2009, and the company’s Form 10-Q for the quarter ended June 30, 2010.

1 2 3 Next › Last »